Glenmark Life Sciences (GLS) is a research driven Indian pharmaceutical company which started as the API (active pharmaceutical ingredients) business unit of Glenmark Pharmaceuticals in 2001, after acquiring the Kurkumbh, Maharashtra site.
The company has moved from being a single manufacturing unit to an independent API company in 2019. It manufactures and supply high quantity non-commoditized API to their customers.
Glenmark Life Sciences (GLS) has four world-class facility where APIs are manufactured. The facilities are located in Ankleshwar & Dahej in Gujarat; and Kurkumbh & Mohol in Maharashtra.
GLS maintain a working relationship with pharmaceutical companies in the USA, Canada, Europe, and Japan.
Dr. Yasir Rawjee is the current Managing Director and Chief Executive Officer of Glenmark Life Sciences
Timeline:
In 2001, Glenmark Pharmaceuticals started the API unit, GLS, and opened the manufacturing plant in Kurkumbh, Maharashtra in 2002.
In 2003, the first product was registered with the USFDA. The acquisition of the Glaxo SmithKline’s (GSK) API manufacturing plant in Ankleshwar, Gujarat was completed the same year. This facility was inspected by USFDA in 2008. Two dugs, Perindopril & Cilazapril were launched.
In 2004, manufacturing at Mohol, Maharashtra was commenced.
Lercanidipine was launched in 2010 with European partners. Voriconazole was launched with Japanese partners in 2013, while Telmisartan was launched with Europe partners the same year.
Ankleshwar plant was inspected by the USFDA IN 2011, and subsequently by the PMDA (Japan) and AFSSAPS (France) in 2012, and COFEPRIS (Mexico) in 2013.
The Dahej, Gujarat plant commenced manufacturing in 2013. This unit located at the special economic zone (SEZ) is the second-largest plant of GLS.
It was inspected by PMDA (Japan) in 2016, and by EDQM (EU), ANSM (France) and USFDA in 2018. Mohol plant was also inspected by the USFDA the same year.
The 1st Generic launches of Ezetimibe and Aprepitant in the US took place in 2016.
The Ankleshwar and Dahej plants were inspected by USFDA in 2015. Esomeprazole Mg Dihydrate was launched, while Etoricoxib and Olmesartan were launched in Europe in 2017.
In 2019, Glenmark Life Sciences became a separate entity and no longer an API unit of Glenmark Pharmaceuticals. The Ankleshwar plant was inspected by USFDA, Health Canada and PMDA (Japan) the same year.
In 2020, GLS embarked upon the manufacture of Favipiravir API for the management of COVID-19 symptoms. GLS was listed on the Indian Stock Exchanges in 2021.
In March 2024, an Indian conglomerate, Nirma, acquired a 75 percent stake in Glenmark Life Sciences (GLS).
GLS is building a new large greenfield project in Solapur in Maharashtra, close to the Mohol plant, to add more capacity.
GLS has 3 USFDA inspected plants. The facilities also have ISO certifications (ISO 14001:2015 and ISO 45001:2018)
They supply high quality APIs to over 700 pharmaceutical companies worldwide. Some of these companies include Aurobindo Pharma, Krka, Teva Pharmaceuticals, Torrent Pharmaceuticals.
Even though the company manufactures APIs, the company also source like 35 to 40% of their chemicals and intermediates from suppliers in China
There are 26 products in the development pipeline, including 2 Iron complexes and 7 Oncology products.
GLS export to 65 countries in North America, Latin America, Europe, Japan, GCC, and CIS countries, India and other countries
Glenmark Life Sciences Product Portfolio
Glenmark Life Sciences develop active pharmaceutical ingredients and now has 146 molecules that cover therapeutic segments like Cardiovascular (CVS) disease, Central Nervous System (CNS) disorders, diabetes, pain management and anti-infectives.
